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Background noise reactionThe indirect ELISA is a widely utilized method to assay serum antibodies. However, a common and critical
problem when analyzing serum antibodies is the disregard for the background noise reaction caused by
the hydrophobic binding of immunoglobulin components in serum components to plastic. Unfortunately,
current blocking agents cannot prevent this background noise reaction. To prevent further misuse of the
ELISA technique, it is important to openly discuss the fundamental problems involved in the ELISA
system.
 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Antibody assay data largely influenced by non-specific reactions
in the indirect ELISA system is often published without evaluating
the reliability and accuracy of the ELISA method, leading to uncer-
tain conclusions in the field of research and clinical medicine. Fur-
thermore, these flawed assay protocols are published and then
incorporated by other researchers, perpetuating this deep-rooted
problem. To prevent further misuse of the ELISA system and misin-
terpretation of assay data, it is important to openly discuss the fun-
damental problems involved in ELISAs.
The indirect ELISA system is almost exclusively used for
assaying antibodies in scientific studies, but without concern for
the various types of false positive and negative reactions involved
in this method. One of the most common and critical problems
when analyzing antibodies in human sera is the disregard for
the background (BG) noise reaction caused by the hydrophobic
binding of immunoglobulin and immune-complexes including
immunoglobulin-rheumatoid factor (RF) complexes in sample
specimens to plastic surfaces. This BG noise reaction is the most
intense type of false positive reaction in this assay system, and
sometimes exceeds the real antibody-antigen reaction, especially
at low serum dilutions. Moreover, it is unique to individual sam-
ples, and is generally higher in sera from patients with diseases
such as rheumatoid arthritis (RA) than in normal controls.
Although the BG OD values of individual samples can be easilydetermined in antigen-uncoated wells and subtracted from the
OD values in antigen-coated wells to obtain the true antibody
value, this key step is often omitted in scientific studies. Conse-
quently, many studies erroneously concluded that antibody levels
are higher in disease groups than in normal controls as discussed
[1].
To avoid this BG noise problem, many commercial diagnostic
kits employ an alternative assay system such as the monoclonal
antibody-based competitive ELISA [2], double-antigen sandwich
ELISA [3–5], or fluid phase assay [6]. These alternative systems
effectively reduce false positive results because secondary antibod-
ies, which detect immunoglobulin bound to plastic surfaces, are
not required. However, the disadvantage of these alternative meth-
ods is that the individual reagents are specific to each assay sys-
tem, and cannot be applied to other antibody assays. Although
these systems are generally useful to assay total antibodies to a
specific antigen, it is difficult to expand this system to assay indi-
vidual antibody subtypes or isotypes. Therefore, the usage of these
alternative methods is very limited and cannot be used for general
purposes. A simple indirect antibody ELISA system is a more
appealing option for various purposes in scientific research.
However, it is important to note that the indirect ELISA cannot
be used to determine human serum antibodies with low dilutions
using current blocking buffer systems [7]. Unfortunately, the
majority of ELISA users are still using BSA or other similar blocking
agents without confirming their blocking ability prior to use
because these blocking agents effectively reduce the OD values in
blank wells (no sample is added), which is a minor non-specific
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reaction depends on the immunoglobulin concentration in the
serum solution, and can be reduced by high dilutions even with
current buffer systems such as 5% BSA-0.2% Tween 20. Therefore,
the use of these buffer systems to determine true antibody levels
is only feasible if the antibody titer is sufficient. Nonetheless,
determining BG OD values in antigen-uncoated wells is required
for all test samples because all test samples have varying degrees
of BG noise and some serum specimens give unpredictably high
BG OD values in these buffer systems.
More importantly, strong protein-protein interactions between
antigens and serum immunoglobulins in these buffer systems
must be considered. For example, BSA does not prevent the non-
specific binding of immunoglobulin to bacterial antigens, whereas
some commercial buffers containing detergents such as Triton X-
100 enhance the non-specific binding of immunoglobulin to target
antigens such as cyclic citrullinated peptide (CCP) [1]. Therefore, an
inhibition test is critical to determine the true antibody levels in
individual samples [1]. Alternatively, undiluted buffered heterolo-
gous serum can be used as a blocking agent to assay antibodies
such as anti-collagen antibodies in RA sera because it prevents
the BG noise reaction caused by RA sera regardless of the presence
of RF [7]. However, the usage of this buffer system is limited,
because heterologous serum contains natural antibodies, which
compete with the antibodies in test samples such as anti-E. coli
antibodies. It also contains a variety of unidentified biological sub-
stances which may interact with the test antigen, such as CCP [1].
Therefore, using heterologous serum may lead to false negative
results.
To demonstrate fundamental problems in the indirect ELISA
system, we have chosen a recent report which specifically dis-
cusses false positive reactions involved in an anti-collagen anti-
body assay, but misinterprets the results [8]. The methods used
in the article illustrate the common mistakes in assaying antibod-
ies at low serum dilutions with inappropriate buffer systems.
Firstly, anti-collagen antibodies were assayed in human sera
diluted at 1/100 with a 1% BSA-buffer system, even though it has
been shown that this buffer system cannot be used to determine
human serum antibodies due to the high BG noise reaction caused
by immunoglobulin components in serum specimens [7]. In the
BSA buffer system, a strong color develops in the entire ELISA plate,
making it difficult to distinguish the antigen-coated wells from
antigen-uncoated control wells.
Secondly, the BG noise reaction of individual samples were
determined in antigen-uncoated BSA-blocked wells, but these val-
ues were not utilized for calculating true antibody unit values of
individual samples. Instead of subtracting the BG OD values from
the OD values in collagen-coated wells, a cut off value obtained
from the normal range was employed to justify the assay data of
test samples. However, the normal range cannot be used as a ref-
erence value to evaluate the sample data, because BG noise reac-
tion values in test samples are likely higher than those of normal
sera. In addition, an inhibition test, which is critical for determin-
ing false positive reaction ratios, was not performed to reveal what
percentage of the assay data is derived from non-specific reactions.
Consequently, the sum of the BG noise value and the antigen-
antibody value was deemed the true antibody value in this study.
It is important to note that these errors are not specific to this arti-
cle, but common practice among users of the ELISA method. These
types of errors need to be addressed because early detection of
antibody responses at low serum dilution might be necessary for
diagnosing infectious diseases and evaluating vaccine efficacy.
The following are basic issues that all ELISA users must under-
stand and take into consideration before setting up an ELISA sys-
tem. In an indirect ELISA, four types of false positive reactions
exist regardless of the antigen type: (1) non-specific binding ofthe ‘‘secondary” antibody to plastic surfaces and antigens (BL value
depends on the antigen: e.g. E. coli > LPS), (2) hydrophobic binding
of immunoglobulin in sample specimens to plastic surfaces (BG
noise reaction), (3) ionic or specific protein-protein interactions
between immunoglobulin in sample specimens and antigens (e.g.
E. coli-immunoglobulin, collagen-fibronectin-immunoglobulin
interaction), and (4) immune-recognition of blocking agents by
natural antibodies in test sera (e.g. antibodies against BSA, heterol-
ogous immunoglobulin, and others). Additionally, three types of
false negative reactions are also involved depending on the types
of blocking agents: (1) competitive inhibition of test antibodies
by antibodies in the blocking/sample dilution buffer containing
heterologous animal serum (e.g. inhibition of antibodies against
bacteria, bacterial toxins, and other environmental agents by the
antibodies in heterologous serum), (2) inhibition of test antibodies
by unidentified components in the blocking/sample dilution buffer
containing heterologous animal serum (e.g. inhibition of anti-CCP
antibodies by normal goat serum component), and (3) denatura-
tion of proteins (enzymes, antigens, and antibodies) or blocking
of antigenic epitopes by ionic detergents such as SDS in the block-
ing/sample dilution buffer. A more in-depth discussion on the indi-
vidual non-specific reactions is beyond the scope of this letter, but
was recently discussed [1]. It proposes a proper assay system with
an appropriate blocking buffer system which prevents all types of
non-specific reactions without affecting the antibody-antigen
reaction.
As discussed, the most common and critical errors in assaying
antibodies by an indirect ELISA system are employment of poor
blocking buffers and failure to subtract the BG OD values in
antigen-uncoated wells from the OD values in antigen-coated
wells. The basic concept of non-specific reactions should be taken
into consideration in any type of immunoassay system because
various types of non-specific reactions are involved in any system
to a certain extent. We encourage everyone that employs the ELISA
system to make an effort to truly understand the principle of ELISA
because it is imperative to reinvestigate ELISA data to dispel the
accumulated misinformed conclusions.
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